Episurf Medical Future Growth

Future criteria checks 2/6

Episurf Medical is forecast to grow earnings and revenue by 23% and 46.2% per annum respectively. EPS is expected to grow by 58.4% per annum. Return on equity is forecast to be -65.8% in 3 years.

Key information

23.0%

Earnings growth rate

58.4%

EPS growth rate

Medical Equipment earnings growth	22.6%
Revenue growth rate	46.2%
Future return on equity	-65.8%
Analyst coverage	Low
Last updated	25 Apr 2024

Recent future growth updates

Recent updates

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Apr 03

We Think Some Shareholders May Hesitate To Increase Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation

May 03

Pål Ryfors Is The CEO & Sales Director of Episurf Medical AB (publ) (STO:EPIS B) And They Just Picked Up 2.3% More Shares

Feb 21

Earnings and Revenue Growth Forecasts

OM:EPIS B - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	65	-48	-51	-43	2
12/31/2025	37	-57	-60	-53	2
12/31/2024	17	-70	-74	-65	2
3/31/2024	11	-92	-93	-85	N/A
12/31/2023	10	-95	-94	-85	N/A
9/30/2023	6	-97	-96	-85	N/A
6/30/2023	5	-94	-88	-78	N/A
3/31/2023	5	-84	-85	-74	N/A
12/31/2022	7	-77	-81	-69	N/A
9/30/2022	14	-72	-74	-63	N/A
6/30/2022	12	-71	-72	-62	N/A
3/31/2022	9	-69	-70	-61	N/A
12/31/2021	7	-69	-67	-60	N/A
9/30/2021	7	-67	-63	-58	N/A
6/30/2021	7	-66	-61	-56	N/A
3/31/2021	5	-63	-60	-55	N/A
12/31/2020	5	-64	-59	-54	N/A
9/30/2020	5	-66	-63	-58	N/A
6/30/2020	5	-69	-63	-59	N/A
3/31/2020	5	-73	-66	-61	N/A
12/31/2019	5	-70	-65	-59	N/A
9/30/2019	5	-66	-62	-55	N/A
6/30/2019	5	-62	-69	-61	N/A
3/31/2019	4	-59	-62	-54	N/A
12/31/2018	4	-58	-62	-52	N/A
9/30/2018	4	-58	-64	-55	N/A
6/30/2018	3	-59	-58	-49	N/A
3/31/2018	3	-55	-70	-62	N/A
12/31/2017	3	-61	N/A	-61	N/A
9/30/2017	3	-64	N/A	-59	N/A
6/30/2017	2	-65	N/A	-59	N/A
3/31/2017	2	-69	N/A	-53	N/A
12/31/2016	2	-62	N/A	-56	N/A
9/30/2016	7	-57	N/A	-55	N/A
6/30/2016	8	-53	N/A	-50	N/A
3/31/2016	7	-48	N/A	-44	N/A
12/31/2015	7	-44	N/A	-38	N/A
9/30/2015	2	-38	N/A	-34	N/A
6/30/2015	2	-34	N/A	-34	N/A
3/31/2015	2	-32	N/A	-30	N/A
12/31/2014	2	-33	N/A	-32	N/A
9/30/2014	3	-31	N/A	-31	N/A
6/30/2014	2	-28	N/A	-31	N/A
3/31/2014	2	-26	N/A	-25	N/A
12/31/2013	2	-23	N/A	-21	N/A
9/30/2013	N/A	-23	N/A	-21	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EPIS B is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EPIS B is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EPIS B is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EPIS B's revenue (46.2% per year) is forecast to grow faster than the Swedish market (1.7% per year).

High Growth Revenue: EPIS B's revenue (46.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EPIS B is forecast to be unprofitable in 3 years.

Episurf Medical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 14%

Consensus revenue estimates decrease by 19%

Price target decreased by 27% to kr4.00

Consensus revenue estimates fall by 20%

Price target decreased to kr5.65

Consensus forecasts updated

Recent updates

Consensus EPS estimates fall by 14%

First quarter 2024 earnings released: kr0.077 loss per share (vs kr0.087 loss in 1Q 2023)

New major risk - Market cap size

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Full year 2023 earnings: EPS and revenues miss analyst expectations

Here's Why Episurf Medical (STO:EPIS B) Must Use Its Cash Wisely

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Episurf Medical AB (Publ) Receives Four Additional Patent Approval Notification

Is Episurf Medical (STO:EPIS B) In A Good Position To Invest In Growth?

Consensus revenue estimates decrease by 19%

Price target decreased by 27% to kr4.00

Third quarter 2023 earnings released

Episurf Medical AB (publ), Annual General Meeting, Apr 09, 2024

Episurf Medical Announces 510(k) Submission for Big Toe Implant

Episurf Members Announces Nomination Committee for Episurf Medical's Annual General Meeting in 2024

Episurf Medical Announces Early Clinical Results from Episealer Talus Study Presented at Scientific Congress

Episurf Medical Announces Prospective Episealer Talus Clinical Study

Episurf Medical AB (publ) Announces First Commercial Case in the US Has Been Scheduled for Surgery

Second quarter 2023 earnings released

Chief Executive Officer recently bought kr660k worth of stock

Will Episurf Medical (STO:EPIS B) Spend Its Cash Wisely?

First quarter 2023 earnings released

Chief Executive Officer recently bought kr72k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Episurf Medical AB (publ), Annual General Meeting, May 04, 2023

Episurf Medical AB (publ) Announces Dennis Stripe Not Stand for Re-Election as Chairman of the Board of Directors

Episurf Medical AB (Publ) Receives Notice of Allowance from the United States Patent and Trademark Office

Episurf Medical AB (publ) Receives FDA 510(k) clearance for Episealer® Patellofemoral System

Consensus revenue estimates fall by 20%

Third quarter 2022 earnings released

Price target decreased to kr5.65

Episurf Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 09, 2024

Episurf Medical Announces That the Episealer® Knee Technology and Clinical Results

Episurf Medical AB (Publ) Appoints Nomination Committee

We're Not Very Worried About Episurf Medical's (STO:EPIS B) Cash Burn Rate

Episurf Medical AB (Publ) Provides Update on 510(K) Application to FDA for the Episealer Patellofemoral System

Episurf Medical Announces New U.S. Patent Approval for Episurf Medical

Episurf Medical AB (Publ) Announces New Patent Approval in Hong Kong for Episurf Medical

Episurf Medical Announces Results from Study with Episealer® Knee Implant Accepted for Presentation at Swedish Orthopaedic Congress

Consensus forecasts updated

Episurf Medical AB (Publ) Announces New Patent Approval in Hong Kong

Second quarter 2022 earnings released

Episurf Medical AB (Publ) Announces First Surgery in India with the Knee Implant Episealer® Has Been Scheduled

First quarter 2022 earnings: Revenues miss analyst expectations

Price target decreased to kr5.65

Episurf Medical Provides Updates of 510(K) Application on Episealer Patellofemoral System

New European Patent Approves for Episurf Medical

Episurf Medical AB (Publ) Announces the Initiation of a Prospective Investigator-Initiated Study with 2 Years Follow-Up of 25 Episealer Talus Patients

First Indian Patent Approval for Episurf Medical

Episurf Medical Receives Reimbursement Coverage for Episealer Talus in Belgium

Episurf Medical AB’s Implants Receive National Regulatory Approval in Hong Kong

Consensus revenue estimates fall by 34%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

The European Patent Office Approves European Patent for Episurf Medical

the European Patent Office EPO Announces Its Intention to Grant Another European Patent for Episurf Medical AB (publ)

Episurf Medical Submits 510(K) Application for Episealer® Patellofemoral System

Board Member recently bought kr798k worth of stock

CEO & Acting Sales Director recently bought kr185k worth of stock

Chief Financial Officer recently bought kr51k worth of stock

Third quarter 2021 earnings released

Episurf Medical (STO:EPIS B) Is In A Good Position To Deliver On Growth Plans

Independent Director recently bought kr98k worth of stock

Episurf Medical AB (Publ) Announces Results from Multicentre Study

Independent Chairman of the Board recently bought kr59k worth of stock

Episurf Medical Announces the Initiation of Prospective Investigator-Initiated European Multicentre Study with 5 Years' Follow-Up of 25 Episealer® Talus Patients

Chief Financial Officer recently bought kr131k worth of stock

Second quarter 2021 earnings released: kr0.08 loss per share (vs kr0.084 loss in 2Q 2020)